FDA Approves First Treatment for Warm Autoimmune Hemolytic Anemia

The FDA has approved IMAAVY (nipocalimab-aahu) as the first specific treatment for warm autoimmune hemolytic anemia (wAIHA) in adults and pediatric patients aged 12 and older. This approval, based on pivotal Phase 2/3 study data, marks a significant advancement for patients with this rare, life-threatening autoantibody disease, offering a new therapeutic option.